long intergenic non-protein coding RNA 1641Genealiases: []
Q-omics provides the consensus-scored LINC01641 profile across patient tissues and cancer cell-line models. LINC01641 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, LINC01641 is differentially expressed in 9, with the highest sampling consensus in BLCA. Additionally, LINC01641 RNA expression shows 6,423 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BRCA, BLCA, and STAD as cancer lineages where LINC01641 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01641 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01641 survival associations across molecular data types. LINC01641 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01641 RNA expression–survival associations across cancer types. High LINC01641 expression shows unfavorable associations in BRCA, KICH, ACC, KIRC, LUAD and LIHC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify BRCA as the clearest survival context for LINC01641 RNA expression.
This table summarizes LINC01641 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01641. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01641 shows lower tumor expression in BLCA, KICH, KIRP and PRAD and higher tumor expression in COAD and LIHC. The BLCA box plot shows higher LINC01641 RNA expression in normal versus tumor tissue (log2 FC = −0.047, t-test p = .025).
This table shows molecular features associated with LINC01641 in patient tissues and cancer cell lines. In patient samples, LINC01641 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
